We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals

166 hedge funds and large institutions have $195M invested in Ironwood Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 48 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

56,558% more call options, than puts

Call options by funds: $14.7M | Put options by funds: $26K

86% more capital invested

Capital invested by funds: $105M → $195M (+$90M)

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

7% more funds holding

Funds holding: 155166 (+11)

1.17% more ownership

Funds ownership: 90.35%91.52% (+1.2%)

8% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 48

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
166
Holders Change
+11
Holders Change %
+7.1%
% of All Funds
2.18%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
30
Increased
52
Reduced
48
Closed
18
Calls
$14.7M
Puts
$26K
Net Calls
+$14.7M
Net Calls Change
+$6.65M
Name Holding Trade Value Shares
Change
Change in
Stake
SP
126
Stonebrook Private
Michigan
$14.4K +$11.4K +10,985 New
EW
127
Evoke Wealth
California
$14.2K +$11.2K +10,835 New
KRW
128
Kaufman Rossin Wealth
Florida
$13.8K +$10.9K +10,516 New
Mackenzie Financial
129
Mackenzie Financial
Ontario, Canada
$13.7K
California State Teachers Retirement System (CalSTRS)
130
California State Teachers Retirement System (CalSTRS)
California
$13.4K +$7 +7 +0.1%
Neuberger Berman Group
131
Neuberger Berman Group
New York
$13.4K -$21K -20,292 -66%
AFGAS
132
Allegiance Financial Group Advisory Services
Virginia
$13.2K +$10.5K +10,108 New
Fisher Asset Management
133
Fisher Asset Management
Washington
$13.1K
ECM
134
EMC Capital Management
Texas
$13K
TRCT
135
Tower Research Capital (TRC)
New York
$12.5K -$19.1K -18,478 -66%
HCA
136
Harbor Capital Advisors
Illinois
$11K +$8.32K +8,037 New
Mirae Asset Global Investments
137
Mirae Asset Global Investments
South Korea
$8.23K +$30 +29 +0.5%
AB
138
Amalgamated Bank
New York
$6K
IA
139
IFP Advisors
Florida
$5.27K +$641 +619 +18%
Osaic Holdings
140
Osaic Holdings
Arizona
$4.76K +$3.45K +3,329 +14,474%
PD
141
Point72 (DIFC)
United Arab Emirates
$4.73K +$3.74K +3,611 New
GFM
142
GF Fund Management
China
$4.44K -$604 -584 -15%
CA
143
Clearstead Advisors
Ohio
$3.97K +$1.57K +1,513 +100%
TWD
144
True Wealth Design
Ohio
$3.09K +$1.39K +1,343 +132%
Optiver Holding
145
Optiver Holding
Netherlands
$2.83K +$2.07K +1,998 +1,218%
W
146
WealthCollab
Washington
$2.58K
PWA
147
Physician Wealth Advisors
Utah
$2.19K
Nisa Investment Advisors
148
Nisa Investment Advisors
Missouri
$2.13K -$439 -424 -21%
Royal Bank of Canada
149
Royal Bank of Canada
Ontario, Canada
$2K -$9.01K -8,709 -85%
SCM
150
Sterling Capital Management
North Carolina
$1.63K +$558 +539 +77%

IRWD Hedge Fund Activity: Q3 2025 in Review

166 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2025, worth a combined $195M — up 86% from $105M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new IRWD positions and 18 closed out — a net gain of 12 holders — while 52 added to existing stakes and 48 trimmed.

The largest buyer was Bank of America, adding an estimated $8.63M. The largest seller was LSV Asset Management, exiting entirely with an estimated $1.97M sold.

  • 166 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2025, up from 155 in Q2 2025.
  • Funds reported $195M of Ironwood Pharmaceuticals stock for Q3 2025, up 86% quarter-over-quarter.
  • 30 funds opened new Ironwood Pharmaceuticals positions in Q3 2025 and 18 closed out, a net change of +12 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q3 2025 was Bank of America, an estimated $8.63M added.
  • The largest Ironwood Pharmaceuticals seller in Q3 2025 was LSV Asset Management, an estimated $1.97M sold.

Based on aggregated 13F filings for Q3 2025.